Ipsogen
Ipsogen is based in Marseilles, France.
It developped an assay that classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights.
LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement. Warnex offers the JAK2 assay in Canada.
Products
JAK2 MutaScreen™ Kits for V617F mutation screening (Link)
- Ipsogen JAK2 MutaScreen™ Kits allow the detection and estimation of % JAK2 V617F mutation from genomic DNA isolated from whole peripheral human blood. This test improves the classification of Philadelphia Negative (Ph-) myeloproliferative diseases.
FusionQuant® Kits are unique molecular kits providing standardisation and accurate quantification of fusion gene transcripts in Leukemia.
ProfileQuant® Kits are unique quantitative molecular kits aimed at standardising, detecting and quantifying the WT1 and BAALC gene transcripts in human cells.
IpsoQuant™ software is a complete data management solution for the molecular follow-up of Leukemia patients.
MLL FusionChip® is a unique patent-protected tool, designed to determine whether a translocation is present on the MLL gene and to accurately determine the MLL partner gene and its relative breakpoint in patients with acute Leukemia. Once the partner gene has been identified this information can be used in follow-up studies to detect minimal residual disease (MRD) using specific RQ-PCR assays.
Ipsogen ProfileQuant® Solid Tumor Marker Kits are unique quantitative molecular kits aimed at standardising, detecting and quantifying gene transcripts in solid tumors. The ProfileQuant® Kits are research tools intended for the accurate normalised quantification of ESR1, ERBB2, GATA3 or SCUBE2 gene transcripts in human cells. (Breast cancer)